The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI

Climacteric

Volumn 15, Issue 3, 2012, Pages 267-274

  Nappi, R E ^a   Davis, S R ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b MONASH UNIVERSITY   (Australia)

Author keywords

HORMONE THERAPY; SEXUAL HEALTH; UROGYNECOLOGICAL HEALTH; WOMEN'S HEALTH INITIATIVE

Indexed keywords

ESTROGEN; GESTAGEN; PRASTERONE; TESTOSTERONE;

ANORGASMIA; DEPRESSION; DYSPAREUNIA; DYSURIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; HORMONAL THERAPY; HUMAN; MENOPAUSE; NOCTURIA; OVERACTIVE BLADDER; POST HOC ANALYSIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SEXUAL ABUSE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL HEALTH; SEXUAL SATISFACTION; STRESS INCONTINENCE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINAL PRURITUS; WOMEN'S HEALTH;

DYSPAREUNIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; URINARY INCONTINENCE; URINARY TRACT INFECTIONS; UROGENITAL SYSTEM; WOMEN'S HEALTH;

EID: 84861378576     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.657589     Document Type: Review

References (84)

1. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22
2. Bachmann GA, Leiblum SR. Sexuality in sexagenarian women. Maturitas 1991;13:45
3. Meston CM. Aging and sexuality. West J Med 1997;167: 285-90. (Pubitemid 27451238)
4. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233-8
5. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53 (Pubitemid 38040534)
6. Nappi RE, Lello S, Melis GB, Albani F, Polatti F, Genazzani AR. LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause. Climacteric 2009;12:533-40
7. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22
8. Barlow DH, Cardozo LD, Francis RM, et al . Urogenital ageing and its effect on sexual health in older British women. BJOG 1997;104:87-91 (Pubitemid 27019901)
9. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292-303 (Pubitemid 39505183)
10. Sampselle CM, Harlow SD, Skurnick J, Brubaker L, Bondarenko I. Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women. Obstet Gynecol 2002; 100:1230-8 (Pubitemid 35449189)
11. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society. Accessed at http://www.menopause.org/edumaterials/ 2004HTrreport.pdf
12. Cardozo L, Bachmann GA, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second Report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7 (Pubitemid 28440818)
13. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103:254-60
14. Hendrix SL, Cochrane BB, Nygaard IE, et al . Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935
15. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol 2001; 97:116-20 (Pubitemid 32057168)
16. Waetjen LE, Johnson WO, Xing G, Feng WY, Greendale GA, Gold EB. Serum estradiol levels are not associated with urinary incontinence in midlife women transitioning through menopause. Menopause 2011;18:1283-90
17. Waetjen LE, Ye J, Feng WY, et al . Association between menopausal transition stages and developing urinary incontinence. Obstet Gynecol 2009;114:989-98
18. Sherburn M, Guthrie JR, Dudley EC, O'Connell HE, Dennerstein L. Is incontinence associated with menopause? Obstet Gynecol 2001;98:628-33 (Pubitemid 32907458)
19. Botlero R, Davis SR, Urquhart DM, Shortreed S, Bell RJ. Agespecific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas 2009;62: 134-9
20. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003;62:45-51 (Pubitemid 41116582)
21. Hillard T. The postmenopausal bladder. Menopause Int 2010;16: 74-80
22. Steinauer JE, Waetjen LE, Vittinghoff E, et al . Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol 2005;106:940-5 (Pubitemid 41532898)
23. Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011;59:387-400
24. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004;83:892-7 (Pubitemid 39331534)
25. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008:CD005131
26. Shaw C. A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity. Eur Urol 2002;42:432-40 (Pubitemid 35396726)
27. Salonia A, Zanni G, Nappi RE, et al . Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol 2004;45:642-8 (Pubitemid 38481693)
28. Serati M, Salvatore S, Uccella S, Nappi RE, Bolis P. Female urinary incontinence during intercourse: a review on an understudied problem for women's sexuality. J Sex Med 2009;6:40-8
29. World Health Organization. Sexual health. In H ealth Topics . Geneva: WHO, 2011
30. Tan HM, Marumo K, Yang DY, Hwang TI, Ong ML. Sex among Asian men and women: the Global Better Sex Survey in Asia. Int J Urol 2009;16:507-14
31. Davison SL, Bell RJ, La China M, Holden SL, Davis SR. The relationship between self-reported sexual satisfaction and general wellbeing in women. J Sex Med 2009;6:2690-7
32. Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressantinduced sexual dysfunction in 2 European countries: a crosssectional patient survey. J Clin Psychiatry 2006;67:204-10 (Pubitemid 43357465)
33. Laumann E, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:531-44
34. Davies S, Katz J, Jackson JL. Sexual desire discrepancies: effects on sexual and relationship satisfaction in heterosexual dating couples. Arch Sex Behav 1999;28:553-67 (Pubitemid 30004898)
35. Brezsnyak M, Whisman MA. Sexual desire and relationship functioning: the effects of marital satisfaction and power. J Sex Marital Ther 2004;30:199-217 (Pubitemid 38470798)
36. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH. Sexual activity and function in middle-aged and older women. Obstet Gynecol 2006;107:755-64
37. Avis NE, Brockwell S, Randolph JF Jr, et al . Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009;16:442-52
38. Davison SL, Bell RJ, LaChina M, Holden SL, Davis SR. Sexual function in well women: stratification by sexual satisfaction, hormone use, and menopause status. J Sex Med 2008;5:1214-22 (Pubitemid 351606707)
39. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970-8
40. Sidi H, Puteh SE, Abdullah N, Midin M. The prevalence of sexual dysfunction and potential risk factors that may impair sexual function in Malaysian women. J Sex Med 2007;4:311-21 (Pubitemid 46394705)
41. Tungphaisal S, Chandeying V, Sutthijumroon S, Krisanapan O, Udomratn P. Postmenopausal sexuality in Thai women. Asia-Oceania J Obstet Gynaecol 1991;17:143-6
42. Nappi RE, Nijland EA. Women's perception of sexuality around the menopause: outcomes of a European telephone survey. Eur JObstet Gynecol Reprod Biol 2008;137:10-16 (Pubitemid 351635671)
43. Blumel JE, Castelo-Branco C, Cancelo MJ, Romero H, Aprikian D, Sarra S. Impairment of sexual activity in middle-aged women in Chile. Menopause 2004;11:78-81 (Pubitemid 40362202)
44. Gass M, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. Menopause 2011;18:1160-71
45. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21 (Pubitemid 32164676)
46. McCall-Hosenfeld JS, Jaramillo SA, Legault C, et al. Correlates of sexual satisfaction among sexually active postmenopausal women in the Women's Health Initiative observational study. J Gen Intern Med 2008;23:2000-9
47. Crandell C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt) 2002; 10:857
48. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-6 (Pubitemid 30347020)
49. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-6
50. Barnabei VM, Cochrane BB, Aragaki AK, et al . Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105: 1063-73 (Pubitemid 40571027)
51. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14: 355-69
52. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92 (Pubitemid 40675125)
53. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-61 (Pubitemid 30249896)
54. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876-83
55. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500
56. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-31
57. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22
58. Somboonporn W, Davis S, Seif M, Bell R. Testosterone for peri-and postmenopausal women. Cochrane Database Syst Rev 2005, updated 2009:CD004509
59. Riley A, Riley E. Controlled studies on women presenting with sexual drive disorder. I. Endocrine status. J Sex Marital Ther 2000;26:269-83 (Pubitemid 30439829)
60. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53 (Pubitemid 41058142)
61. Levin RJ. Human male sexuality: appetite and arousal, desire and drive. In Legg C, Boott D, eds. Human Appetite: Neural and Behavioural Bases. New York: Oxford University Press, 1994: 127-64
62. Schober JM, Pfaff D. The neurophysiology of sexual arousal. Best Pract Res Clin Endocrinol Metab 2007;21:445-61 (Pubitemid 47387102)
63. Pfaff D, Frohlich J, Morgan M. Hormonal and genetic influences on arousal-sexual and otherwise. Trends Neurosci 2002;25: 45-50 (Pubitemid 34093785)
64. Kapp B, Cain M. The neural basis of arousal. In Smelser N, Baltes P, eds. The International Encyclopedia of Social and Behavioral Sciences . Oxford: Elsevier Science, 2001:1463-6
65. Lee AW, Pfaff DW. Hormone effects on specific and global brain functions. J Physiol Sci 2008;58:213-20
66. Giraldi A, Marson L, Nappi R, et al . Physiology of female sexual function: animal models. J Sex Med 2004;1:237-53 (Pubitemid 40424633)
67. Hays J, Okene J, Brunner R, Kotchen J, Manson JE, Patterson R. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54 (Pubitemid 36532310)
68. Brunner RL, Gass M, Aragaki A, et al . Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 2005;165: 1976-86 (Pubitemid 41362620)
69. Dennerstein L, Lehert P, Burger H. The relative effects of hormone and relationship factors on sexual function of women through the natural menopause transition. Fertil Steril 2005;84:174-80 (Pubitemid 40991478)
70. Davison SL, Bell RJ, Lachina M, Holden SL, Davis SR. Sexual function in well women: stratification by sexual satisfaction, hormone use, and menopause status. J Sex Med 2008;5:2690-7
71. Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al . Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of arandomized active-controlled trial. J Sex Med 2008;5:646-56
72. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579-90
73. Kritz-Silverstein D, von Muhlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc 2008;56:1292-8
74. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-7 (Pubitemid 24181005)
75. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704
76. Lobo R, Rosen RC, Yang H-M, Block B, Van der Hoop R. Comparative effects of oral esterifi ed estrogens with and without methyl testosterone on endocrine profi les and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52 (Pubitemid 36687880)
77. Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ. Combined esterifi ed estrogens and methyltestosterone versus esterifi ed estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 2005;12: 374-84 (Pubitemid 41098650)
78. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-31
79. Simon J, Braunstein G, Nachtigall L, et al . Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33 (Pubitemid 41262278)
80. Shifren J, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006;13:770-9
81. Davis SR, Moreau M, Kroll R, et al . Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl JMed 2008;359:2005-17
82. Goldstat R, Briganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause 2003;10:390-8
83. El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10:335-43 (Pubitemid 47123955)
84. Snabes MC, Berry SD, Berry DA, Zborowski JD, White WB. Low cardiovascular event rate in postmenopausal women with increased cardiac risk: initial findings from the ongoing blinded Libigel (testosterone gel) cardiovascular safety study. Presented at 92nd Annual Meeting of the Endocrine Society , San Diego, USA, 2010